Navigation Links
Novocure Presents Preclinical Data at the American Association for Cancer Research (AACR)
Date:4/10/2013

WASHINGTON, April 10, 2013 /PRNewswire/ -- Novocure announced today that new data from preclinical testing of NovoTTF Therapy in non-small cell lung carcinoma (NSCLC), ovarian and pancreatic cancer has been presented at the 2013 AACR Annual Meeting.  The new data builds on existing published research describing the potential efficacy of NovoTTF Therapy in a wide range of solid tumors.

"The results presented at the AACR Annual Meeting demonstrate that NovoTTF Therapy inhibits the growth of squamous histology non-small cell lung cancer as well as pancreatic and ovarian cancers in preclinical models," said Eilon Kirson , M.D., Ph.D., Novocure's Chief Science Officer and Head of Research and Development.  "We intend to build on this research through clinical trials evaluating the efficacy of NovoTTF Therapy in these indications when delivered in combination with chemotherapy."

AACR Annual Meeting 2013 Abstracts

  • Giladi et al, Development of an orthotopic squamous cell carcinoma (SCC) lung cancer model.  Data were presented describing a new in vivo model to test the efficacy of anti-neoplastic treatments in SCC lung cancer.  Abstract #340.
  • Giladi et al, NovoTTF Therapy inhibited the growth of pancreatic and ovarian cancer in vitro. Additionally, the data supports a conclusion that modulation of NovoTTF Therapy frequency may overcome treatment resistance. Abstract #5569.

About NovoTTF Therapy
NovoTTF Therapy is delivered by portable, non-invasive medical devices designed for continuous use throughout the day by the patient. NovoTTF Therapy has been shown in in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate. The delivery systems weigh about six pounds and create a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division. The NovoTTF-100A System is not approved in the US for any indications except for recurrent glioblastoma brain tumors. The safety and effectiveness of NovoTTF Therapy in lung, pancreas and ovarian cancers has not been established.

About Novocure™
Novocure Limited is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors. Novocure's US operations are based in New York, NY and Portsmouth, NH and the company's research center is located in Haifa, Israel. For additional information about the company, please visit www.novocure.com.

Contact:
Frank Leonard
(212) 767-7536
media@novocure.com  


'/>"/>
SOURCE Novocure
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Novocure™ to Present NovoTTF™ Therapy Data at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology
2. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
3. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
4. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
5. Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Trial Blood Samples at 2013 American Association of Cancer Research Annual Meeting
6. Cardium Presents Year-End 2012 Financial Results And Recent Developments
7. Pharmagen Presents to North Carolina General Assembly at N.C. Bios Legislative Breakfast
8. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
9. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
10. Versus Presents New Hand-Hygiene Alliance, Wireless Sensors and RTLS Education at HIMSS13
11. University Hospitals Case Medical Center Presents Study On The Elimination Of Retained Surgical Sponges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Inc., the creator of the drug Truveta for the treatment ... IPO. The United States spends approximately ... prescription epilepsy drug being $450.00-$1200.00 for a one month supply. ... AXIUM PHARMACEUTICALS, INC ... is the fact that Americans spent $42 billion on anxiety medications last ...
(Date:8/11/2017)... , Aug. 11, 2017 DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... August 14 and host a conference call at 9:00am ... operating and financial results and its strategy and outlook ... hosted by Erez Raphael , Chief Executive Officer, ...
(Date:8/7/2017)... 7, 2017 Insightin Health, provider of ... and engagement, announced the selection of Michael ... Development, effective as of February 2017. In this role, ... strategy for our clients. Wood brings with him ... and business analytics within the healthcare industry. Wood ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... ... Pot Valet is a leading provider of premium medical-grade cannabis in California. ... soon, every state in the country, the company offers patients safe, legal, and discreet ... , According to Pot Valet, all California patients have the legal right to ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... Great Employers , an international competition, were announced today. The awards recognize the ... and suppliers who help to create and drive great places to work. , ...
(Date:8/16/2017)... , ... August 16, 2017 , ... The next Patient ... being accepted. , Students who successfully complete the seven-week long Patient Care Academy ... Assistant (CNA). The average starting salary for a CNA in Kalamazoo is $24,428.* , ...
(Date:8/16/2017)... Houston, Texas (PRWEB) , ... August 16, 2017 , ... ... Community Credit Union's Stars in the Classroom and will win a visit by a ... in grades K-12 who are at least five years old can visit texanschecking.com/stars to ...
(Date:8/16/2017)... ATLANTA, Georgia (PRWEB) , ... August 16, 2017 ... ... practice in Atlanta, opened their doors. They celebrate 30 years in business this ... to create an up-to-date, inviting, tranquil space to serve their patients. , ...
Breaking Medicine News(10 mins):